A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
Clinical trial NCT06165146 · COMPLETED
Trial details
- NCT number
- NCT06165146
- Sponsor
- Eli Lilly and Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-10
- Primary completion
- 2020-12-30
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.